NAMPT and diabetes mellitus: Moreover, there is a meta-analysis suggesting that visfatin/eNampt may be a promising biomarker not only for predicting obesity, diabetes status, insulin resistance, or metabolic syndrome but also for the development of cardiovascular disease35.